Compounds > 7-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
Page last updated: 2024-12-09

7-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID613848
CHEMBL ID342685
CHEBI ID108982
SCHEMBL ID11821347

Synonyms (28)

Synonym
CHEMDIVAM_001248
OPREA1_384904
smr000514198
MLS001207807
OPREA1_670749
CHEMDIV1_028331
7-methyl-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one
MIXCOM6_000523
7-methyl-5-phenyl-1,3-dihydro-2h-1,4-benzodiazepin-2-one
STK387439
CHEBI:108982
CHEMBL342685
AKOS001210553
7-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
HMS667H17
HMS2815G08
2,3-dihydro-7-methyl-5-phenyl-1h-1,4-benzodiazepin-2-one
5571-63-1
SCHEMBL11821347
1h-benzo[e]1,4-diazepin-2(3h)-one, 7-methyl-5-phenyl-
7-methyl-5-phenyl-1,3-dihydro-2h-1,4-benzodiazepin-2-one #
ZZLQGKUTUGIQNL-UHFFFAOYSA-N
Q27187962
sr-01000393160
SR-01000393160-1
DTXSID50346662
Z57156346
EN300-26874710
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzodiazepineA group of heterocyclic compounds with a core structure containing a benzene ring fused to a diazepine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
P53Homo sapiens (human)Potency70.79460.07319.685831.6228AID504706
importin subunit beta-1 isoform 1Homo sapiens (human)Potency0.00465.804836.130665.1308AID540253
snurportin-1Homo sapiens (human)Potency0.00465.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency0.00465.804816.996225.9290AID540253
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glycogen synthase kinase-3 alphaHomo sapiens (human)AC5039.00000.013529.7434171.7000AID463203
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID1150161Sedative activity in mouse1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Electronic factors in the structure-activity relationship of some 1,4-benzodiazepin-2-ones.
AID13306-Log C was determined by performing the incl screen test1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Decomposition of pharmacological activity indices into mutually independent components using principal component analysis.
AID1150163Taming activity in mouse assessed as suppression of electrical current-induced aggressive behavior by foot-shock test1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Electronic factors in the structure-activity relationship of some 1,4-benzodiazepin-2-ones.
AID13308-Log C was determined by performing the pentylenetetrazole test1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Decomposition of pharmacological activity indices into mutually independent components using principal component analysis.
AID1150162Muscle relaxant activity in mouse1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Electronic factors in the structure-activity relationship of some 1,4-benzodiazepin-2-ones.
AID13305-Log C was determined by performing the foot shock test1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Decomposition of pharmacological activity indices into mutually independent components using principal component analysis.
AID13304-Log C was determined by performing the electroshock minimum test1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Decomposition of pharmacological activity indices into mutually independent components using principal component analysis.
AID1150164Anticonvulsion activity in mouse assessed as protection against pentylenetetrazole-induced convulsion1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Electronic factors in the structure-activity relationship of some 1,4-benzodiazepin-2-ones.
AID13307-Log C was determined by performing the maximum electroshock test1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Decomposition of pharmacological activity indices into mutually independent components using principal component analysis.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (28.57)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's3 (42.86)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.06 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ro 5-4864
4'-chlorodiazepam: selectively binds peripheral benzodiazepine receptor		1.9510
clioquinol
Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.. 5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.		1.9510monohydroxyquinoline;
organochlorine compound;
organoiodine compound		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator
clonazepam
Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.. clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.		1.95101,4-benzodiazepinone;
monochlorobenzenes		anticonvulsant;
anxiolytic drug;
GABA modulator
nordazepam
Nordazepam: An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.. nordazepam : A 1,4-benzodiazepinone having phenyl and chloro substituents at positions 5 and 7 respectively; it has anticonvulsant, anxiolytic, muscle relaxant and sedative properties but is used primarily in the treatment of anxiety.		2.36201,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator;
human metabolite;
sedative
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		2.36201,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
fludiazepam
fludiazepam: RN given refers to parent cpd; structure		1.95101,4-benzodiazepinone;
organochlorine compound;
organofluorine compound		anxiolytic drug
flunitrazepam
Flunitrazepam: A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.. flunitrazepam : A 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia.		2.36201,4-benzodiazepinone;
C-nitro compound;
monofluorobenzenes		anxiolytic drug;
GABAA receptor agonist;
sedative
nimetazepam
nimetazepam : A nitrazepam which is substituted at positions 1 by a methyl group. It is used as an anticonvulsant and as a hypnotic for the short-term management of insomnia.		2.36201,4-benzodiazepinone;
C-nitro compound		anticonvulsant;
antispasmodic drug;
GABA modulator;
sedative
nitrazepam
Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic.. nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome).		2.36201,4-benzodiazepinone;
C-nitro compound		anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative
cm 7116
norflutoprazepam: structure		2.3620benzodiazepine
chlordesmethyldiazepam
[no description available]		2.3620benzodiazepine
n-desmethylflunitrazepam
[no description available]		2.3620
7-bromo-5-phenyl-1,2-dihydro-2h-1,4-benzodiazepin-2-one
7-bromo-5-phenyl-1,2-dihydro-2H-1,4-benzodiazepin-2-one: RN given refers to unlabeled parent cpd		2.3620
2-chlorodiazepam
[no description available]		2.3620
ro 5-3438
Ro 5-3438: structure		1.9510
n-desmethylflunitrazepam
N-desmethylflunitrazepam: metabolite of flunitrazepam		2.3620
ro 05-4082
ID 690: methyl deriv of clonazepam; structure		1.9510
ConditionIndicatedRelationship StrengthStudiesTrials
Absence Seizure
[description not available]		01.9510
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		01.9510
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510